Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

Published positive Phase 2 trial results of onvansertib in combination with FOLFIRI ... resources are sufficient to fund its operations into Q1 2026. Total operating expenses were approximately $12.8 ...

Learn how accounts payable are recorded on a balance sheet, why they’re classified as liabilities and their role in managing ...

Made progress deploying all components of the Nanox solution including Nanox.ARC and Expanded US sales and support staff a key component of global ...

Non-GAAP adjusted diluted net income per ADS was RMB0.05 (US$nil) in the third quarter of 2024, compared to basic and diluted net loss per ordinary share of RMB0.15 in the same period of 2023. Each ...

Exploring high dividend stocks with yields of 13-14% but potential risks, including the possibility of dividend cuts in the ...

Alpha DaRT® accepted into the prestigious Total Product Life Cycle Advisory Program (TAP) of the FDA, to accelerate market access to the Alpha ...

Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical ...

Closed an Upsized and Oversubscribed $13 Million Public Offering to Fund Near-term Commercialization Milestones ...

Notes payable, plus accrued interest, totaled approximately $6.9 million. The current portion of the notes payable plus ...

WESTLAKE VILLAGE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter ...

before deducting placement fees and offering expenses. The financing will fund execution of the Phase 2b ‘702’ trial in Pulmonary Arterial Hypertension (PAH) and general corporate purposes. Added ...